Close

Merck (MRK) Announces EU Approval of KEYTRUDA Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative Breas

Go back to Merck (MRK) Announces EU Approval of KEYTRUDA Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative Breas
Merck & Co. (NYSE: MRK) Delayed: 131.95 +0.20 (0.15%)
Previous Close $131.75    52 Week High $65.46 
Open $132.00    52 Week Low $47.97 
Day High $132.28    P/E 89.76 
Day Low $131.08    EPS $1.47 
Volume 10,201,476